Oncotarget.net features press releases on the latest oncology research, as well as interviews from the distinguished network of authors who continue to publish their research with Oncotarget.

Tag: HER2

Oncotarget

HER2-Low Breast Cancer: Genomic Insights and Evolving Treatment Paradigms

January 22, 2025

“Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a new clinical subtype of breast cancer, benefiting from treatment with novel anti-HER2 antibody-drug conjugates.” BUFFALO, NY… read more

Figure 2: Analysis of immune cell subsets during neoadjuvant therapy.

Oncotarget

Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer

March 27, 2024

“[...] this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]” BUFFALO, NY- March 27, 2024 – A new… read more

Oncotarget

The Uncharted Role of HER2 Mutant Alleles in Breast Cancer

November 6, 2023

“Our research study has demonstrated that poziotinib is highly potent in neratinib-resistant HER2 L755S lobular and ductal breast cancer models [...].” BUFFALO, NY- November 6, 2023 – A new editorial… read more

Oncotarget

Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer

September 13, 2023

“With these new drugs now available in clinical practice, we expect HER2+/HER2-low BC patients with BMs to live longer and to live better.” BUFFALO, NY- September 13, 2023 – A… read more